{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:36:09Z","timestamp":1791401769298,"version":"4.3.3"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013172","name":"SymBio Pharmaceuticals Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015234","name":"Sunesis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.clml.2018.12.009","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T23:02:28Z","timestamp":1545260548000},"page":"142-148.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"19","author":[{"given":"Abhishek","family":"Maiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-9659","authenticated-orcid":false,"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesid","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maro","family":"Ohanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.12.009_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/CCO.0000000000000404","article-title":"Relapsed\/refractory acute myeloid leukemia: any progress?","volume":"29","author":"Schlenk","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2018.12.009_bib2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clml.2018.12.009_bib3","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/leu.2011.66","article-title":"Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy","volume":"25","author":"Steelman","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.12.009_bib4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cell.2017.02.013","article-title":"Doubling down on mutant RAS can MEK or break leukemia","volume":"168","author":"Tothova","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clml.2018.12.009_bib5","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1038\/sj.leu.2404009","article-title":"Mutations of genes in the receptor tyrosine kinase (RTK)\/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia","volume":"19","author":"Christiansen","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.12.009_bib6","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-13-3270","article-title":"Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia","volume":"20","author":"Johnson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.12.009_bib7","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.12.009_bib8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/leu.2010.22","article-title":"AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions","volume":"24","author":"Haferlach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.12.009_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc4000","article-title":"MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road","volume":"15","author":"Caunt","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2018.12.009_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2018.12.009_bib11","first-page":"127","article-title":"K-ras as a target for cancer therapy","volume":"1756","author":"Friday","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clml.2018.12.009_bib12","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","article-title":"Preclinical efficacy of MEK inhibition in Nras-mutant AML","volume":"124","author":"Burgess","year":"2014","journal-title":"Blood"},{"issue":"15 suppl","key":"10.1016\/j.clml.2018.12.009_bib13","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/jco.2011.29.15_suppl.6506","article-title":"Phase I\/II trial of the MEK1\/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed\/refractory myeloid malignancies: evidence of activity in pts with RAS mutation","volume":"29","author":"Borthakur","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.009_bib14","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies: Trametinib in RAS-Mutant Malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.12.009_bib15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1078-0432.CCR-13-1311","article-title":"Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial","volume":"20","author":"Jain","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"8 suppl","key":"10.1016\/j.clml.2018.12.009_bib16","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1158\/1538-7445.AM10-2515","article-title":"Abstract 2515: preclinical development of ARRY-162, a potent and selective MEK 1\/2 inhibitor","volume":"70","author":"Lee","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.12.009_bib17","doi-asserted-by":"crossref","first-page":"S663","DOI":"10.1016\/S0959-8049(15)30062-9","article-title":"A\u00a0phase 1b\/2 study of ribociclib (LEE011; CDK4\/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma","volume":"51","author":"Herpen","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2018.12.009_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.12.009_bib19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/bjc.2017.10","article-title":"A\u00a0phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor","volume":"116","author":"Bendell","year":"2017","journal-title":"Br J Cancer"},{"issue":"15 suppl","key":"10.1016\/j.clml.2018.12.009_bib20","doi-asserted-by":"crossref","first-page":"9051","DOI":"10.1200\/jco.2014.32.15_suppl.9051","article-title":"A\u00a0phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors","volume":"32","author":"Juric","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.009_bib21","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.009_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2018.12.009_bib23","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","article-title":"PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers","volume":"69","author":"Wee","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.12.009_bib24","doi-asserted-by":"crossref","first-page":"8736","DOI":"10.1158\/0008-5472.CAN-10-0902","article-title":"Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells","volume":"70","author":"Gopal","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.12.009_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nature08279","article-title":"Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras","volume":"461","author":"Lauchle","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.clml.2018.12.009_bib26","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1002\/ijc.24604","article-title":"Intrinsic resistance to the MEK1\/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1\/2 signalling and\/or strong PI3K signalling in colorectal cancer cell lines","volume":"125","author":"Balmanno","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2018.12.009_bib27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2217\/fon-2017-0170","article-title":"A\u00a0review of binimetinib for the treatment of mutant cutaneous melanoma","volume":"13","author":"Koelblinger","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2018.12.009_bib28","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1038\/bcj.2015.103","article-title":"Clinical, pharmacokinetic and pharmacodynamic data for the MEK1\/2 inhibitor pimasertib in patients with advanced hematologic malignancies","volume":"5","author":"Ravandi","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2018.12.009_bib29","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2009-01-198093","article-title":"A\u00a0randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.009_bib30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2012.09165.x","article-title":"The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML","volume":"158","author":"Burnett","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.12.009_bib31","doi-asserted-by":"crossref","first-page":"14835","DOI":"10.18632\/oncotarget.11730","article-title":"MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations","volume":"8","author":"Kerstjens","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2018.12.009_bib32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.15282","article-title":"MEK1\/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment","volume":"182","author":"Crassini","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.12.009_bib33","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1172\/JCI74182","article-title":"Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm","volume":"124","author":"Kong","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2018.12.009_bib34","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood.V99.9.3461","article-title":"Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK\/MAPK pathways in acute myelogenous leukemia","volume":"99","author":"Milella","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.009_bib35","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1158\/0008-5472.CAN-04-0866","article-title":"Blocking the Raf\/MEK\/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis","volume":"64","author":"Wu","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.12.009_bib36","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.009_bib37","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cell.2017.01.020","article-title":"KRAS allelic imbalance enhances fitness and modulates MAP kinase dependence in cancer","volume":"168","author":"Burgess","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clml.2018.12.009_bib38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1172\/JCI12807","article-title":"Therapeutic targeting of the MEK\/MAPK signal transduction module in acute myeloid leukemia","volume":"108","author":"Milella","year":"2001","journal-title":"J\u00a0Clin Invest"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018306797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018306797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:54Z","timestamp":1761870714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018306797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2152265018306797"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.12.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}